Strata Critical Medical, Inc. (SRTA)
NASDAQ: SRTA · Real-Time Price · USD
4.350
-0.050 (-1.14%)
At close: Dec 5, 2025, 4:00 PM EST
4.410
+0.060 (1.38%)
After-hours: Dec 5, 2025, 5:56 PM EST
Strata Critical Medical Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Strata Critical Medical stock have an average target of 7.63, with a low estimate of 7.25 and a high estimate of 8.00. The average target predicts an increase of 75.40% from the current stock price of 4.35.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Strata Critical Medical stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|
| Strong Buy | 1 | 1 | 2 |
| Buy | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 1 | 1 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Lake Street | Lake Street | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +83.91% | Dec 2, 2025 |
| Lake Street | Lake Street | Strong Buy Maintains $6.5 → $7.25 | Strong Buy | Maintains | $6.5 → $7.25 | +66.67% | Sep 17, 2025 |
Financial Forecast
Revenue This Year
190.46M
from 248.69M
Decreased by -23.42%
Revenue Next Year
265.20M
from 190.46M
Increased by 39.24%
EPS This Year
-0.09
from -0.35
EPS Next Year
0.08
from -0.09
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 199.9M | 283.5M | |
| Avg | 190.5M | 265.2M | |
| Low | 179.4M | 245.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -19.6% | 48.9% | |
| Avg | -23.4% | 39.2% | |
| Low | -27.8% | 28.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.09 | 0.08 | |
| Avg | -0.09 | 0.08 | |
| Low | -0.09 | 0.08 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.